Inhibitors of lfa-1 binding to icams and uses thereof
CA 2369005 A1 · Owner: Staunton, Donald E. · Inventors: Staunton, Donald E.; Fowler, Kerry; Orme, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to compounds that bind to a novel regulatory site in the I domain of LFA-1, and thereby inhibit LFA-1 binding to ICAMs that bind LFA-1. The present invention therefore also provides methods to regulate leukocyte adhesion to endothelial cells. Compounds of the ivnention are useful for the treatment of pathologies, such as those associated inflammatory diseases, autoimmune diseases, tumor metastasis allograft rejection and , reperfusion injury. In particular the present invention is directed to diaryl sulfides of general structural formula (I) a pharmaceutically acceptable , salt, or prodrug thereof and to the use of diaryl sulfides, and particularly …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 3, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 3, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 3, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.